Moberg Pharma announces that Peter Wolpert, founder and CEO of Moberg Pharma, has divested 164,601 shares in Moberg Pharma.
Following the divestment, Peter Wolpert holds 435,399 shares, remaining one of the ten largest shareholders in the company. Furthermore, he holds stock options entitling him to subscribe for another 125,000 shares.
“The divestment is made for personal financial reasons and I don’t intend to sell additional shares. I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company”, says Peter Wolpert, CEO of Moberg Pharma.
The transaction has been reported to Sweden’s financial supervisory authority (Finansinspektionen) according to regulations.